Skip to main content
. Author manuscript; available in PMC: 2017 Feb 27.
Published in final edited form as: J Immunol. 2017 Jan 27;198(5):2105–2114. doi: 10.4049/jimmunol.1601563

Figure 3. OxLDL-ICs prime the inflammasome using multiple receptors.

Figure 3

(A) Surface expression of FcγRs on BMDCs was measured by flow cytometry. Shown is one representative of 3 experiments. (B) BMDCs were pre-treated with the TLR-4 inhibitor CLI-095 prior to treatment with oxLDL-IC or oxLDL-Fab2 for 3 hrs and ATP for an additional hr. Culture supernatants were tested for IL-1β by ELISA. Shown is one of 3 experiments with similar results. Unlike letters denote significance (p<0.01) by One-way ANOVA with a Bonferroni post-test. (C) BMDCs from Myd88−/− (left) and Cd36−/− (right) mice (n=3 per group) were treated with oxLDL or oxLDL-ICs for 3 hrs followed by ATP for an additional hr. IL-1β in culture supernatants was measured by ELISA. Unlike letters denote significance (p<0.01) by Student’s t test. Error bars represent SEM.